Apavac, a Simple Autologous Vaccination Process (AV) Associated with Clinical Efficacy in 56 Patients (pts) Having Cancer (C) and 11 Pts Having Hematological Malignancies (HM)
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-118862
Abstract: Introduction. Nowadays, immune therapy is a major therapy for C. Vaccination was developed for more than 20 years (y) with less than 20% of responses (R) associated with a mild advantage in overall survival (OS)… read more here.
Keywords: plt followed; plt; followed lasting; cancer ... See more keywords
The outcome of patients (pts) with metastatic colorectal cancer (mCRC) based on site of metastases (mets) and the impact of molecular markers and site of primary cancer on metastatic pattern.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.3560
Abstract: 3560Background: Although liver is the commonest site of mets in pts with CRC, pattern of spread is variable and may reflect different biology in different subsets of pts. Methods: This is a retrosp... read more here.
Keywords: pattern; outcome patients; site; cancer ... See more keywords
Cisplatin/5-FU (CF) +/- panitumumab (P) for patients (pts) with non-resectable, advanced, or metastatic esophageal squamous cell cancer (ESCC): An open-label, randomized AIO/TTD/BDGO/EORTC phase III trial (POWER).
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.4011
Abstract: 4011Background: Most ESCC pts have advanced disease at time of diagnosis. Chemotherapy (CTX) is used to improve quality of life (QoL) and overall survival (OS), but still with limited impact. Prior... read more here.
Keywords: resectable advanced; panitumumab patients; cisplatin panitumumab; pts non ... See more keywords
Characteristics of patients (pts) receiving end of life treatment (EOLT) at an NCI-Designated Cancer Center.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.e18245
Abstract: e18245Background: End of life treatment is identified as a high cost low return intervention and is under evaluation as a quality measure for providers. A 2012 ASCO expert panel acknowledged it as ... read more here.
Keywords: end life; characteristics patients; patients pts; life treatment ... See more keywords
Palbociclib (P) in patients (Pts) with pancreatic cancer (PC) and gallbladder or bile duct cancer (GBC) with CDKN2A alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.2532
Abstract: 2532Background: The TAPUR Study is a phase II multi‐basket study that evaluates the anti‐tumor activity of commercially available targeted agents in pts with advanced cancers with genomic alteratio... read more here.
Keywords: study; palbociclib patients; tapur study; cancer ... See more keywords
Somatic DNA mutations, tumor mutational burden (TMB), and MSI Status: Association with efficacy in patients (pts) with metastatic colorectal cancer (mCRC) of FIRE-3 (AIO KRK-0306).
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.3591
Abstract: 3591Background: FIRE-3 compared 1st-line therapy with FOLFIRI plus either cetuximab or bevacizumab in 592 KRAS exon 2 wt mCRC patients (pts). Methods: Tumor DNA was profiled by next-generation sequ... read more here.
Keywords: dna mutations; fire; mutations tumor; patients pts ... See more keywords
Outcomes in patients (pts) who had received sorafenib (S) as the only prior systemic therapy in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC).
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.4088
Abstract: 4088Background: C inhibits tyrosine kinases including MET, VEGFR, and AXL. In the CELESTIAL trial, C improved overall survival (OS) and progression-free survival (PFS) compared with P in pts with a... read more here.
Keywords: trial; outcomes patients; pts received; celestial trial ... See more keywords
Single-center analysis of 109 patients (pts) with metastatic chromophobe renal cell carcinoma (ChRCC): Differences in outcomes by histologic variant.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.4577
Abstract: 4577Background: ChRCC constitutes 5-10% of all RCC cases, and is generally associated with better prognosis including benefit from approved targeted agents (Armstrong, Lancet Onc, 2016). Presence o... read more here.
Keywords: single center; 109 patients; analysis 109; chrcc ... See more keywords
Immune profile and outcomes of patients (pts) with gynecological malignancies (GYN) enrolled in early phases immunotherapy (IO) trials.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.5595
Abstract: 5595Background: Immune checkpoint inhibitors have shown promising activity in multiple tumor types. However, there are no approved IO for GYN. Methods: We identified GYN pts treated with IO from 20... read more here.
Keywords: gynecological malignancies; pts gynecological; outcomes patients; immune profile ... See more keywords
Acalabrutinib in patients (pts) with Waldenström macroglobulinemia (WM).
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.7501
Abstract: 7501Background: Bruton tyrosine kinase (BTK) is a clinically validated target in WM. Acalabrutinib is a highly selective, potent, covalent BTK inhibitor that we evaluated in a Phase 2 study of pts ... read more here.
Keywords: waldenstr macroglobulinemia; pts waldenstr; acalabrutinib; acalabrutinib patients ... See more keywords
Clinical benefit for minority patients (pts) with advanced refractory cancer versus non Hispanic whites (NHW) when enrolled on early phase (I) clinical trials.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.e18634
Abstract: e18634Background: Minority pts have poor representation in clinical trial participation, and little data exists specifically about phase I trials. These represent a valuable option for pts with adv... read more here.
Keywords: clinical benefit; minority; pts advanced; patients pts ... See more keywords